New data from meta-analysis of Livalo (pitavastatin) in patients with Dyslipidaemia-Kowa Pharmaceuticals
Kowa Pharmaceuticals America, Inc., announced that results of a meta-analysis of 15 randomized, controlled clinical trials, to assess the effects of Livalo (pitavastatin) on glycemic parameters and new-onset diabetes (NOD) in non-diabetic individuals showed that pitavastatin had no significant adverse effect on parameters of glucose metabolism [fasting blood glucose (FBG) or HbA1c] or NOD.
Overall results confirmed no significant differences associated with pitavastatin versus placebo/other statins were observed for FBG [mean difference (95% CI): -0.01(-0.77-0.74); for HbA1c: -0.03 (-0.11-0.05)] or for NOD [risk ratio: 0.70 (0.30-1.61); risk difference: -0.00 (-0.00-0.00)]. Data were presented as a late-breaking abstract at the 83rd European Atherosclerosis Society (EAS) Congress.
Comment: Livalo offers an attractive treatment option for some clinically complex patients on multiple medications, due to its distinct pharmacological characteristics, including a low drug-drug interaction. It has also shown strong efficacy in metabolic syndrome patients without effect on HbA1C levels, as well as in elderly patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins